Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$365 Mln
Revenue (TTM)
$109 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
141.3
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$1.8
EPS
$-0.1
Face value
--
Shares outstanding
179,722,750
CFO
$-116.66 Mln
EBITDA
$-393.58 Mln
Net Profit
$-664.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Century Therapeutics Inc (IPSC)
| 114.1 | -8.2 | 114.1 | 371.4 | -15.0 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Century Therapeutics Inc (IPSC)
| -1.5 | -69.3 | -35.3 | -67.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Century Therapeutics Inc (IPSC)
|
2.1 | 364.8 | 109.2 | -9.6 | -13.8 | -6 | -- | 2.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an... iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. Address: 25 North 38th Street, Philadelphia, PA, United States, 19104 Read more
COO & Head of Early Development
Dr. Adrienne Farid Ph.D.
COO & Head of Early Development
Dr. Adrienne Farid Ph.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Century Therapeutics Inc (IPSC) is $2.13 (NASDAQ) as of 02-Apr-2026 16:37 EDT. Century Therapeutics Inc (IPSC) has given a return of -15.01% in the last 3 years.
Since, TTM earnings of Century Therapeutics Inc (IPSC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.03
|
0.54
|
|
2024
|
-0.63
|
0.49
|
|
2023
|
-1.43
|
1.06
|
|
2022
|
-2.27
|
0.98
|
|
2021
|
-5.30
|
1.28
|
The 52-week high and low of Century Therapeutics Inc (IPSC) are Rs 3.04 and Rs 0.34 as of 04-Apr-2026.
Century Therapeutics Inc (IPSC) has a market capitalisation of $ 365 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Century Therapeutics Inc (IPSC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.